CureVac is readying for the distribution of its COVID-19 vaccine

Pharmaceutical

CureVac, a German biopharma company, is readying for the distribution of CVnCOV, its mRNA-based COVID-19 vaccine, which potentially could receive approval in June.

CEO, Franz Werner Haas, CureVac, highlighted that the organisation is planning for approval in the EU in the second quarter; however, this will depend on the vaccine results from late-stage trials. The results are expected in the following weeks, with the fully enrolled Phase II/III vaccine trials.

“CureVac is readying for the distribution of its COVID-19 vaccine.“

The European Commission has secured 225 million doses of the vaccine, with the potential to purchase another 180 million.

Haas stated: "mRNA has emerged as a key technology that leads the charge against the COVID-19 pandemic, but it is only starting to realise its full potential in the development of new prophylactic vaccines and therapeutics in other areas such as oncology.”

See all the latest jobs in Pharmaceutical
Return to news